News on immunoassay systems and applications.
The company has seen a sharp rise in test revenues but still struggles with poor stock performance and could soon see new competition for OVA1.
The company said it will use the funds to accelerate expansion of its MeMed BV test, which distinguishes between bacterial and viral infections.
The agreement gives Quanterix an opportunity to explore the clinical utility of its Nf-l marker without having to move its instruments into the clinical space.
The company posted $1.3 million in revenues with OVA1 test sales up 82 percent to 3,602 and revenue per test down 8 percent to $345.
The firm, which went public in September said that full-year 2019 revenues are expected to be between $40 million and $431 million.
